Fulcrum Therapeutics (FULC) Equity Ratio (2019 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Equity Ratio for 7 consecutive years, with 0.95 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 2.21% to 0.95 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.95, a 2.21% increase, with the full-year FY2025 number at 0.95, up 2.21% from a year prior.
- Equity Ratio was 0.95 for Q4 2025 at Fulcrum Therapeutics, up from 0.92 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.95 in Q4 2025 to a low of 0.8 in Q2 2021.
- A 5-year average of 0.9 and a median of 0.92 in 2023 define the central range for Equity Ratio.
- Biggest YoY gain for Equity Ratio was 22.55% in 2021; the steepest drop was 4.61% in 2021.
- Fulcrum Therapeutics' Equity Ratio stood at 0.9 in 2021, then decreased by 2.51% to 0.88 in 2022, then rose by 4.0% to 0.91 in 2023, then grew by 2.14% to 0.93 in 2024, then increased by 2.21% to 0.95 in 2025.
- Per Business Quant, the three most recent readings for FULC's Equity Ratio are 0.95 (Q4 2025), 0.92 (Q3 2025), and 0.94 (Q2 2025).